Imagine a smart delivery system that acts like a GPS for medicine, sending healing signals only to the parts of the body that are inflamed. Instead of treating the whole body and risking side effects, this tool attaches a specialized protein to a 'homing device' that finds damaged blood vessels. Once it arrives, it tells the immune system to calm down and stop attacking healthy tissue.
Current IL-2 therapies lack specificity, leading to systemic side effects and reduced efficacy. There is a need for a delivery mechanism that targets only inflamed tissues in cardiovascular and autoimmune diseases.
A pipeline for preclinical evaluation of IL-2IT candidates and specific anti-OSE scFv antibodies that bind to atherosclerotic plaques.
If you are a drug development firm dealing with the side effects of systemic immune stimulants — this project developed a 3rd-generation IL-2 targeted to inflammatory sites that increases therapeutic efficacy compared to native IL-2 in mice.
If you are a specialized biotech startup dealing with atherosclerosis or myocardial infarction treatments — this project developed an IL-2IT fusion protein that specifically binds to lipid-rich regions of plaques in humans and mice.
If you are an ATMP developer dealing with delivery challenges for immune regulators — this project developed two gene expression systems using AAVs and mRNA to administer targeted immunotherapy.
Based on available project data, there is no information regarding the specific production costs or pricing of the IL-2IT candidates.
The project is currently in the preclinical development phase, focusing on animal models (mice and macaques). Industrial scaling data is not yet provided in the report.
Based on available project data, the consortium has identified and analyzed more than 20 different antibodies to generate specific scFv antibodies, but licensing terms are not disclosed.
The project period runs from 2023-06-01 to 2028-05-31, focusing on preclinical validation in mice and macaques before moving toward clinical application.
It improves upon 1st-generation native IL-2 and 2nd-generation muteins by adding a targeting mechanism (OSE-Ab) to ensure the drug reaches inflammatory sites specifically.
The consortium is research-heavy with 6 universities and 2 research institutes, balanced by 2 industry SMEs. This 20% industry ratio suggests a strong academic foundation with a clear path toward commercial translation, coordinated by Sorbonne University across 6 countries.
Pr David Klatzmann, Sorbonne University
Contact us to explore licensing opportunities for the anti-OSE scFv antibodies.
